Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has recently gained significant recognition as a powerful weight loss medication
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB
Regulatory Issues: Some pharmacies are using unapproved salt forms of semaglutide, which do not comply with FDA standards for compounded drugs
Clinical metabolomics analyses reveal that IBD patients have lower butyrate concentrations and a much lower number of butyrate-producing bacteria (Faecalibacterium prausnitzii and Roseburia hominis) than healthy controls (196198)
These doses were necessary to achieve measurable CNS effects in rodents, but sublingual or subcutaneous routes allow effective dosing at 15mg in research contexts